About Living Pharma
Living Pharma is a Healthcare company based in Baltimore (United States) founded in 2015, and was acquired by Lentigen in July 2017. Personalized anti-tag CAR T cell therapies for cancer are developed. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Insitro, BridgeBio and Celgene; 3 of its 3 listed competitors have raised funding.
Company details
Living Pharma develops personalised CAR T Cell therapies to treat cancer. They are focused on developing therapeutic immuno-oncology products optimised for each individual patient. The companys Universal Anti-Tag Chimeric Antigen Receptor (AT-CAR) engineered T cell can be tailored to each individual patients cancer and disease phenotype. AT-CAR T cells recognize a tagged tumor-targeting molecule (which could be an anti-tumor MAb, Soluble T Cell Receptor, or a Cytokine). The companys universal AT-CAR T cells target and eradicate multiple cancer types through the use of a panel of ATCs, each ATC recognizing a unique tumor-associated antigen.
- Headquarters Baltimore, United States
- Stage Acquired
- SectorsHealthcare
- Website livingpharma.com
- Acquired by Lentigen (Jul 2017)
Investors in Living Pharma
Living Pharma has secured backing from 1 investor. Prominent investors backing the company include Lentigen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Lentiviral vectors are developed for pre-clinical and clinical applications. | 2004 | lentigen.com | Gaithersburg, United States |
Investor details for Living Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Living Pharma
2 dated milestones of Living Pharma across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Living Pharma is founded.
- Exit Acquired by Lentigen.
Competitors of Living Pharma
Living Pharma has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Celgene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. |
Detailed competitors of Living Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Living Pharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Living Pharma
Living Pharma was founded in 2015.
Living Pharma is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Living Pharma develops personalised CAR T Cell therapies to treat cancer. They are focused on developing therapeutic immuno-oncology products optimised for each individual patient. The companys Universal Anti-Tag Chimeric Antigen Receptor (AT-CAR) engineered T cell can be tailored to each individual patients cancer and disease phenotype. AT-CAR T cells recognize a tagged tumor-targeting molecule (which could be an anti-tumor MAb, Soluble T Cell Receptor, or a Cytokine). The companys universal AT-CAR T cells target and eradicate multiple cancer types through the use of a panel of ATCs, each ATC recognizing a unique tumor-associated antigen.
Living Pharma has 1 investor. Key investors include Lentigen.
Yes. Living Pharma was acquired by Lentigen in July 2017.